Genprex Inc. GNPX Archives - Page 4 of 12

WednesdayJun 07, 2023 2:58 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (‘NSCLC’) humanized mouse models. Genprex’s ONCOPREX(R) Nanoparticle Delivery System is a novel non-vital approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for intravenous delivery of various tumor suppressor genes, and potentially…

FridayJun 02, 2023 9:15 am

Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment

Gene Therapy's Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga. Click Here for the full article The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex's innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer. The featured video highlights the compelling story of Jacqueline Marino, a participant in the Phase 1 segment of Genprex's Phase 1/2 Acclaim-1 clinical trial. Marino, diagnosed with non-small cell lung cancer (“NSCLC”), offers an inspiring account…

WednesdayMay 17, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments,…

MondayMay 10, 2021 12:22 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity Emerging Growth Invitational, the Benzinga Small Cap Conference and the CEO Roadshow Webinar Series. Genprex’s CEO and President Rodney Varner will lead the presentations, which will highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer (“NSCLC”). An archive of the presentations will be available for a period of time following the conferences…

ThursdayMay 06, 2021 3:02 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center in Houston, Texas, to grant to Genprex an exclusive worldwide license to an additional portfolio of six patents and one patent application and related technology (“newly licensed IP”). The newly licensed IP includes methods for treating non-small cell lung cancer (“NSCLC”) by administration of a TUSC2 therapeutic in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to…

WednesdayMay 05, 2021 12:14 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the company’s lead drug candidate, REQORSA(TM) immunogene therapy, with AstraZeneca’s Tagrisso(R) (osimertinib) in patients with late-stage NSCLC with mutated epidermal growth factor receptors (“EGFRs”), whose disease progressed after treatment with Tagrisso. “The purpose of IRB review is to assure that appropriate steps…

TuesdayMay 04, 2021 12:18 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). An open-label, multicenter Phase 1/2 clinical trial, Acclaim-2 combines Genprex’s lead drug candidate, REQORSA(TM) immunogene therapy, with Merck & Co Inc.’s Keytruda in patients with late-stage NSCLC who are low expressors (1% to 49%) of the protein programmed death-ligand 1 ("PD-L1"). “Our clinical team remains focused on engaging with leading clinical investigators and esteemed research institutions in…

WednesdayApr 21, 2021 10:06 am

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Varner will answer questions following each week’s presentation. The webinar series is slated to run from April 22 through June 10, 2021, and will begin at 11 a.m. EDT; each presentation is scheduled to last 30 minutes. The company also noted that a recorded version of each webinar would be available on the company website as…

MondayApr 12, 2021 12:15 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. The data were presented at the 2021 American Association of Cancer Research (“AACR”) annual meeting. “We are pleased to have these positive data that provide further support…

MondayApr 05, 2021 12:18 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean. The event is slated to take place virtually from April 6-9, 2021, with company presentations available for on-demand viewing throughout the entirety of the conference. Organized by the Alliance for Regenerative Medicine, the four-day virtual conference will feature more than 80 dedicated company presentations by leading public and private companies, highlighting recent technical and clinical achievements in the areas…

Site Search

Company Search

Tag: Genprex Inc. GNPX